Navigation Links
Lexicon Announces Top-Line Phase 2a Data for LX2931 in Patients with Rheumatoid Arthritis
Date:12/14/2010

of additional higher doses of LX2931 as an orally-delivered treatment for rheumatoid arthritis," said Dr. Arthur T. Sands, president and chief executive officer of Lexicon.  "While we were disappointed by the unusually high placebo effect in this trial, we are encouraged by the excellent overall safety profile observed in the first test of this new mechanism of action in patients with RA."  

The company intends to commence discussions with potential pharmaceutical partners to pursue further development of LX2931 in rheumatoid arthritis.

Clinical Trial

The recently completed study was a 12-week, randomized, double-blind, placebo-controlled study in 208 patients on stable dose methotrexate with progressing rheumatoid arthritis. Patients were randomized to receive either placebo (n=49) or LX2931, 70 mg (n=55), 110 mg (n=54), or 150 mg (n=50), once daily for 12 weeks.  In addition to measurements to assess the drug's safety, efficacy endpoints included the primary endpoint, ACR20 at week 12, as well as secondary endpoints of ACR20, ACR50, ACR70 and DAS28 at weeks 4, 8 and 12.  The trial was conducted at sites within the United States and Eastern Europe.

About S1P Lyase and the Role of S1P in Autoimmune Disease

S1P lyase is responsible for the irreversible degradation of S1P, a biologically active lipid that can act as a second messenger in signal transduction pathways important for immune function.  Changes in local S1P concentrations and gradients in immune tissues can modify lymphocyte migration, inflammatory cell response, and affect barrier function of endothelial cells.  Inhibiting S1P lyase results in an increase in S1P levels, primarily in lymphoid tissues.  The physiological outcome of raising S1P levels in the lymphoid system is immune-modulation, which offers new opportunities for treating autoimmune and inflammatory
'/>"/>

SOURCE Lexicon Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Lexicon to Present Research Results at American Chemical Society Meeting Regarding Target of LX1031 Drug Candidate
2. Lexicon Reports Initial Clinical Trial Results for LX1031, an Investigational New Drug for Irritable Bowel Syndrome
3. Lexicon Files Investigational New Drug Application for LX2931 as a Potential Treatment for Rheumatoid Arthritis
4. Lexicon Initiates Phase 2a Trial of LX6171 Drug Candidate for Cognitive Disorders
5. Lexicon Presents Clinical Data on LX1032 for Carcinoid Syndrome at European Neuroendocrine Tumor Society Meeting
6. Lexicon Pharmaceuticals Provides Clinical Pipeline Update and Reports 2009 First Quarter Results
7. Lexicons Drug Candidate LX1032 for Carcinoid Syndrome Receives Orphan Drug Designation From EMEA
8. Lexicon Completes Phase 1 Clinical Trial and Initiates Phase 2 Clinical Trial of LX4211 in Patients With Type 2 Diabetes
9. Lexicon Announces Pricing of Common Stock in Public Offering
10. Lexicon Announces Completion of Public Offering of Common Stock
11. Lexicon Pharmaceuticals to Present at the 12th Annual BIO CEO & Investor Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2014)... 19, 2014 According to ... (Cryotherapy, Heat, therapy, Hydrotherapy), Accessories (Posture Mirror, Exercise Ball), ... technologies - Global Forecast to 2019" published by ... reach $19,786.3 Million by 2019 from $14,240.0 Million ... 2014 to 2019. Browse 74 market ...
(Date:9/19/2014)... , Sept. 19, 2014  4WEB Medical announces ... 3D-printed foot and ankle osteotomy implants on the ... Ankle Society annual meeting in Chicago ... all of a surgeon,s osteotomy needs with 74 size options ... systems had smaller offerings of only 15 to 18 implant ...
(Date:9/19/2014)... STATION, N.J. , Sept. 19, 2014 Merck (NYSE: ... United States and Canada , is ... Desafiando La Diabetes: Logra Tus Metas , an educational program ... their blood sugar -- a key treatment goal to help reduce ... United States are at a higher risk for developing ...
Breaking Medicine Technology:Physiotherapy Equipment Market Worth $19,786.3 Million by 2019 2Physiotherapy Equipment Market Worth $19,786.3 Million by 2019 3Physiotherapy Equipment Market Worth $19,786.3 Million by 2019 44WEB Medical Unveils 3D-Printed Osteotomy Truss System 2Celebrity Chef Leticia Moreinos Schwartz Partners with Merck on Desafiando La Diabetes: Logra Tus Metas to Urge Hispanics With Type 2 Diabetes to Get to Their A1C Goal 2Celebrity Chef Leticia Moreinos Schwartz Partners with Merck on Desafiando La Diabetes: Logra Tus Metas to Urge Hispanics With Type 2 Diabetes to Get to Their A1C Goal 3Celebrity Chef Leticia Moreinos Schwartz Partners with Merck on Desafiando La Diabetes: Logra Tus Metas to Urge Hispanics With Type 2 Diabetes to Get to Their A1C Goal 4Celebrity Chef Leticia Moreinos Schwartz Partners with Merck on Desafiando La Diabetes: Logra Tus Metas to Urge Hispanics With Type 2 Diabetes to Get to Their A1C Goal 5
... TRIANGLE PARK, N.C. , June 2 ... it has received a letter from the U.S. Food ... its respiratory products Serevent® and Advair®.  The letter concludes ... committee meetings regarding the safety profile of long-acting beta2-agonists ...
... June 2 The Georgia Advanced Surgery ... first fully accredited surgical center for performing all ... true outpatient setting – has officially opened. ... highly advanced, minimally invasive surgical techniques that spare ...
Cached Medicine Technology:GSK Announces Revised Product Labels for Serevent® and Advair® 2New Georgia Advanced Surgery Center Provides Women Many Unique Benefits 2
(Date:9/20/2014)... Winston-Salem, NC (PRWEB) September 20, 2014 The excitement ... held in Mount Airy, North Carolina. This year the Surry ... that draws people from around the country who are still fans ... Griffith Show is a sitcom that aired on CBS from 1960 ... 9th best show in American television history. Mount Airy, North ...
(Date:9/20/2014)... 2014 Plumbing construction services ... 5, indicating a moderately favorable purchasing environment for buyers. ... current and future pricing trends that will limit the ... factors that negatively affect buyer power are a lack ... the moderate switching costs. Buyers benefit, however, from low ...
(Date:9/20/2014)... 20, 2014 Final Cut Pro X ... release of the Information theme for FCPX filmmakers. , “Fun, ... describe the Information theme,” says Christina Austin, CEO of Pixel ... so professional.” , Information features easy to use controls that ... the environment. Change the background color, color of each circle ...
(Date:9/20/2014)... Nevada (PRWEB) September 20, 2014 ... extremely successful showing at the PAIN Week conference ... Cosmopolitan Hotel and Casino in Las Vegas from ... MarijuanaDoctors.com primarily attended PAIN Week in the hopes ... as a viable and legitimate tool to treat ...
(Date:9/19/2014)... (PRWEB) September 19, 2014 “Copay coupons,” ... sales of brand drugs among patients with prescription drug ... according to a new report from the Department ... General (OIG). Federal anti-kickback laws prohibit suppliers from offering ... by the federal government. , The report highlights that ...
Breaking Medicine News(10 mins):Health News:Mayberry Days Parade Cars will be Provided by Mount Airy Toyota and Mount Airy Chrysler Dodge Jeep Ram 2Health News:Plumbing Construction Services Procurement Category Market Research Report from IBISWorld Has Been Updated 2Health News:Plumbing Construction Services Procurement Category Market Research Report from IBISWorld Has Been Updated 3Health News:Plumbing Construction Services Procurement Category Market Research Report from IBISWorld Has Been Updated 4Health News:Today Pixel Film Studios Announced the Release of the Information Theme for Final Cut Pro X 2Health News:MarijuanaDoctors.com Experiences Unprecedented Support and Growth at Pain Week 2014 2Health News:PCMA: New OIG Report Cites Drug Manufacturer“Copay Coupon” Use in Medicare Part D 2
... Unit in Leeds receives Lilly,s 2008 Global ... ... Inc. (NYSE:,CVD), a leading provider of drug development services, today announced ... Lilly and Company., Covance,s clinical research unit based in Leeds, ...
... According to recent,reporting, including today,s Washington ... is circulating a draft proposed,regulation that, if ... providers to withhold the critical health care ... about their care. As a leading health,care ...
... Data for Second ... Quarter 2008 ... July 31 Sunrise Senior Living,Inc. (NYSE: SRZ ) today announced that ... the Securities and Exchange Commission,("SEC"). The Company also reported preliminary selected financial and,operating ...
... in chronic kidney cases , , THURSDAY, July 31 (HealthDay ... routinely measured marker of bone disease -- may signal ... for chronic kidney disease, say U.S. researchers. , The ... a three-year period. It found that patients with alkaline ...
... Therapeutics,Inc. (Nasdaq: HALO ), a biopharmaceutical company ... that it will release financial results for the ... market open on Friday, August 8, 2008., ... Gregory Frost,PhD, Vice President and Chief Scientific Officer, ...
... WEST CHESTER, Ohio, July 31 AtriCure, Inc.,(Nasdaq: ATRC ), ... today announced that it will present at the following,investor conferences during ... August 6, 2008 at the Millennium Broadway ... and Chief Executive Officer, is scheduled to present at 9:00 ...
Cached Medicine News:Health News:Covance Recognized for Outstanding Customer Service by Eli Lilly and Company 2Health News:SPOKESPERSON AVAILABILTY: Planned Parenthood President Available for Interviews on Proposed HHS Regulations 2Health News:Sunrise Files 2007 Form 10-K 2Health News:Sunrise Files 2007 Form 10-K 3Health News:Sunrise Files 2007 Form 10-K 4Health News:Sunrise Files 2007 Form 10-K 5Health News:Sunrise Files 2007 Form 10-K 6Health News:Sunrise Files 2007 Form 10-K 7Health News:Sunrise Files 2007 Form 10-K 8Health News:Sunrise Files 2007 Form 10-K 9Health News:Sunrise Files 2007 Form 10-K 10Health News:Sunrise Files 2007 Form 10-K 11Health News:Bone Disease Test Shows Death Risk for Dialysis Patients 2Health News:Halozyme Therapeutics to Hold Pipeline Update Conference Call on August 8 2Health News:AtriCure to Present at the BMO Focus on Healthcare and Canaccord Adams Global Growth Conferences in August 2
The cementless acetabular shells form part of the Mallory head range of femoral and acetabular implants....
The Trilogy system builds on the success of the Harris/Galante Porous and HGP II cups by combining proven features with new technology designed to inhibit the formation and migration of polyethylene ...
The Secur-Fit cups incorporate enhancements derived from years of clinical, radiographic, and implant retrieval observations....
The Bofor acetabular revision cup addresses cases of severe acetabular destruction....
Medicine Products: